First and only steerable delivery system designed to help seal the left atrial appendage (LAA) in people with atrial fibrillation who are at an increased risk of stroke Now available in the U.S., ...

Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation The trial met the primary safety ...

CHICAGO -- For patients at high risk of stroke who underwent catheter-based atrial fibrillation ablation, left atrial appendage closure led to less bleeding compared with oral anticoagulation, the ...

(MENAFN- GlobeNewsWire - Nasdaq) The global left atrial appendage closure (LAAC) devices market is projected to register a robust growth from 2025 to 2033. Market growth is underpinned by a rapidly ...

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...

Please provide your email address to receive an email when new articles are posted on . OPTION is a head-to-head trial of left atrial appendage closure with Watchman FLX vs. anticoagulation after ...

On the first day of the 2016 CardioStim sessions, I am happy to report a "positive" study on percutaneous left atrial appendage closure [1]. Notice I did not write Watchman. In Europe, the majority of ...

A Comprehensive Linked Registry for the Post-Market Evaluation of Cardiovascular Devices: Rationale and Design of the Massachusetts Cardiovascular [MassCar] Registry Receive the the latest news, ...

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

We’re talking about treatment when it comes to different heart conditions. Dr. Steven Hearne is an interventional cardiologist and co-director of the Guerrieri Heart & Vascular Institute at Peninsula ...